Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.
The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by MarketWatch Top; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Newseze's algorithm reads the story and answers your question — calmly, factually, with source attribution. No comments, no flame wars — just answers.
No questions yet. Be the first.
Answers reflect Newseze's editorial framework applied under fair use (17 U.S.C. § 107). Not financial, legal, medical, or tax advice. Hate speech and racial slurs are blocked.
Related stories
Why it mattersThe European Central Bank is set to keep borrowing costs steady as it weighs bond-market turmoil in France and a renewed advance in energy costs. Bloomberg's Oliver Crook reports from Frankfurt.
The European Central Bank is set to keep borrowing costs steady as it weighs bond-market turmoil in France and a renewed advance in energy costs. Bloomberg's Ol…
Why it mattersGDP and inflation figures arrive together at 8:30 a.m. Eastern time.
GDP and inflation figures arrive together at 8:30 a.m. Eastern time. Strong growth and persistent price pressures could strengthen the case for an interest-rate…
Why it mattersGold dipped after the Federal Reserve kept interest rates unchanged and offered little guidance on its next move, leaving traders guessing over the prospect of a hike before year-end.
Why it mattersBrazil’s state-controlled oil producer Petrobras lifted production to a record and ran its refineries near full capacity in the third quarter, helping the country weather disruptions to global energy markets from the Ira…